5 Crescent Drive
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
2965 articles with GlaxoSmithKline
The brands Stada is picking up include venous treatment Venoruton, Coldrex for colds, Cetebe vitamin C supplements, Mebucaine for sore threats and Tavegyl for allergies, among others.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older).
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
2/6/2020One day after GlaxoSmithKline began to outline some of the broad strokes of splitting the company into two separate entities, more details are coming into place – particularly staffing concerns over the integration of the company’s vaccine business into its pharma operations.
One entity will focus on pharmaceuticals and drug development, while the other will be aimed at consumer healthcare.
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Belantamab mafodotin accepted for accelerated assessment by the EMA's Committee for Human Medicinal Products (CHMP)
People can express their #TUMSworthy moments with the blue dot emoji to win big
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) granted a priority review for the company's Biologics License Application (BLA) seeking approval of belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health coverage
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
What's New at the J.P. Morgan Life Healthcare Conference?
Emma Walmsley, chief executive officer of GlaxoSmithKline, is predicting a good year for her company, with the potential of six regulatory approvals in the United States.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
According to an analysis conducted on Jan. 1, more than 250 drugs manufactured by different companies saw price increases.
The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.